Amyris signs up to $255M synthetic cannabinoid partnership
Amyris signs up to $255M synthetic cannabinoid partnership The passage details a commercial biotech agreement for synthetic cannabinoid production. It mentions a sizable financial figure but involves only a private company and an undisclosed partner, with no direct links to high‑ranking officials, government agencies, or controversial wrongdoing. The lead is low‑value for investigative purposes. Key insights: Amyris entered a partnership in Feb 2019 valued up to $255 million.; Payments include upfront and milestone‑based tranches over 12‑36 months.; The partner is undisclosed, focusing on CBD production via synthetic biology.
Summary
Amyris signs up to $255M synthetic cannabinoid partnership The passage details a commercial biotech agreement for synthetic cannabinoid production. It mentions a sizable financial figure but involves only a private company and an undisclosed partner, with no direct links to high‑ranking officials, government agencies, or controversial wrongdoing. The lead is low‑value for investigative purposes. Key insights: Amyris entered a partnership in Feb 2019 valued up to $255 million.; Payments include upfront and milestone‑based tranches over 12‑36 months.; The partner is undisclosed, focusing on CBD production via synthetic biology.
Tags
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.